Leap Therapeutics, Inc. (LPTX)
NASDAQ: LPTX · Real-Time Price · USD
3.090
-0.010 (-0.32%)
At close: Jan 14, 2025, 4:00 PM
3.060
-0.030 (-0.97%)
After-hours: Jan 14, 2025, 4:42 PM EST
Leap Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Leap Therapeutics stock have an average target of 7.50, with a low estimate of 5.50 and a high estimate of 9.00. The average target predicts an increase of 142.72% from the current stock price of 3.09.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 15, 2024.
Analyst Ratings
The average analyst rating for LPTX stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 2 | 2 | 2 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5.5 | Strong Buy | Reiterates | $5.5 | +77.99% | Nov 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5.5 | Strong Buy | Reiterates | $5.5 | +77.99% | Aug 13, 2024 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +158.90% | Jun 28, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $5.5 | Strong Buy | Maintains | $7 → $5.5 | +77.99% | May 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +126.54% | Mar 19, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.87
from -3.98
EPS Next Year
-1.29
from -1.87
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | n/a | |||
| Avg | n/a | n/a | n/a | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.90 | -1.12 | -0.83 | |||
| Avg | -1.87 | -1.29 | -1.20 | |||
| Low | -1.82 | -1.55 | -1.82 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.